Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.

NEW YORK, February 04, 2025 -- ( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...